Haemonetics Stock News

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

BOSTON, April 6, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2022 financial results at 6:00 am EDT on Tuesday, May

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Haemonetics Corporation <>, a supplier of plasma collection devices, is trading lower on Thursday after the U.S

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

BOSTON, Feb. 23, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 43rd Annual Institutional Investors Conference on Monday, March 7, 2022, at 9:50 a.m. ET. The…

Haemonetics Corporation (NYSE:HAE) shares, rose in value on Friday, 02/18/22, with the stock price up by 1.65% to the previous days close as strong demand from buyers drove the stock to $55.52. Actively observing the price movement in the last trading, the stock closed the session at $54.62, falling within a range of $54.59 and Haemonetics Corporation (NYSE: HAE): A Great Stock To Watch Read More »

Haemonetics Corp. (HAE) shares closed this week 25.9% higher than it did at the end of last week. The stock is currently up 9.4% year-to-date, down 57.2% over the past 12 months, and up 54.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $58.90 and as low as $44.98 this week.Shares closed 57.7% below its 52-week high and 34.4% above its 52-week low.Trading volume this week was 4.5% higher than the 10-day average and 38.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -311.9% The company's stock price performance over the past 12 months lags the peer average by -1210.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 378.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

The stock price of Haemonetics Corporation (NYSE: HAE) increased by 16.16% in the most recent trading session. This is why it happened.

Haemonetics Corp. (HAE) shares closed today 16.2% higher than it did at the end of yesterday. The stock is currently down 11.4% year-to-date, down 66.3% over the past 12 months, and up 26.4% over the past five years. Today, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 0.8%. Trading Activity Shares traded as high as $49.25 and as low as $44.98 this week.Shares closed 61.6% below its 52-week high and 25.4% above its 52-week low.Trading volume this week was 34.4% higher than the 10-day average and 42.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 103.9% The company's stock price performance over the past 12 months lags the peer average by -1595.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 182.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.